Immunic, Inc. · NASDAQ:IMUX

Immunic — Digital Novel Coronavirus Investment Forum (July 2020)

5 slides from Immunic's conference presentation, Jul 7, 2020

Slide 1: Targeting COVID-19 with IMU-838
Immunic THERAPEUTIES ~~) Targeting COVID-19 with IMU-838 NASDAQ: IMUX | July 8, 2020 | Digital Novel Coronavirus Investment Forum
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995, All statements, other than statements of his
Slide 3: Development Pipeline
Development Pipeline Program | Indication Target Preclinical Phase 1 Phase 2 Phase 3 IMU-838 Multiple Sclerosis DHODH = Ulcerative Colitis DHODH —EE Crohn's Disease DHODH sy | PSC DHODH ee i CovID-19 DHODH ———~—~—~-Sll—™s IMU-935 Psoriasis RORyt EE Orphan Al Diseases RORyt EE IMU-856 al eer ——= i =
Slide 4: IMU-838: Triple Attack on COVID-19
IMU-838: Triple Attack on COVID-19 IMU-838 is an advanced clinical drug candidate with attractive pharmacokinetic, safety and tolerability profile with more than 650 individuals exposed to date IMU-838 attacks COVID-19 disease by three complementary mechanisms: 1 | Inhibition of virus replication by
Slide 5: Thank you!
Thank you! Immunic, Inc. 1200 Ave of the Americas, Suite 200 Chief Scientific Officer New York, NY 10036 Phone: +49 89 2080 477 03 Ushi Email: hella.kohlhof@imux.com & Immunic 5 | @lmmunic, nc. | 08.07.2020